Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme

Figure 2

Kaplan-Meier survival curves of progressive-free survival and overall survival categorized according to the patients’ KPS and MGMT status. Differences were analyzed with the log-rank test. Progressive-free survival was significantly higher () in KPS ≥ 70 patients (a) and methylated patients (c), compared with KPS < 70 patients and unmethylated patients. Overall survival was significantly higher () in KPS ≥ 70 patients (b), compared with KPS < 70 patients. The difference in the overall survival between methylated and unmethylated patients was not significant (d).

(a)

(b)

(c)

(d)